Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Beijing Kawin Technology Share-Holding Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥23.50 |
52 Week High | CN¥37.63 |
52 Week Low | CN¥18.50 |
Beta | 0.92 |
11 Month Change | 4.07% |
3 Month Change | -22.39% |
1 Year Change | 20.39% |
33 Year Change | -10.17% |
5 Year Change | n/a |
Change since IPO | -44.05% |
Recent News & Updates
Shareholder Returns
688687 | CN Biotechs | CN Market | |
---|---|---|---|
7D | 4.1% | -1.7% | -0.7% |
1Y | 20.4% | -20.9% | -19.1% |
Return vs Industry: 688687 exceeded the CN Biotechs industry which returned -20.9% over the past year.
Return vs Market: 688687 exceeded the CN Market which returned -19.1% over the past year.
Price Volatility
688687 volatility | |
---|---|
688687 Average Weekly Movement | 6.0% |
Biotechs Industry Average Movement | 5.7% |
Market Average Movement | 5.6% |
10% most volatile stocks in CN Market | 8.9% |
10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 688687's share price has been volatile over the past 3 months.
Volatility Over Time: 688687's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 584 | Desheng Zhou | www.kawin.com.cn |
Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China. The company’s products include recombinant human interferon alfa-2b injection; vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; and compound glycyrrhizin.
Beijing Kawin Technology Share-Holding Co., Ltd. Fundamentals Summary
688687 fundamental statistics | |
---|---|
Market cap | CN¥4.01b |
Earnings (TTM) | CN¥117.53m |
Revenue (TTM) | CN¥1.43b |
33.5x
P/E Ratio2.7x
P/S RatioIs 688687 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688687 income statement (TTM) | |
---|---|
Revenue | CN¥1.43b |
Cost of Revenue | CN¥243.33m |
Gross Profit | CN¥1.19b |
Other Expenses | CN¥1.07b |
Earnings | CN¥117.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.70 |
Gross Margin | 83.01% |
Net Profit Margin | 8.21% |
Debt/Equity Ratio | 5.9% |
How did 688687 perform over the long term?
See historical performance and comparison